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ABSTRACT
The outcome of unrelated donor bone marrow transplantation for aplastic anemia is inferior to that of sibling
donor bone marrow transplantation because of a higher rate of transplant-related mortality (TRM), which is
closely associated with the intensity of pretransplant conditioning to overcome graft rejection. We conducted
a prospective trial with an intermediate to high dose of total body irradiation (TBI) in combination with a fixed
dose of cyclophosphamide (120 mg/kg) to use for pretransplant conditioning for unrelated donor bone marrow
transplantation in adult aplastic anemia. The number of patients who received doses of 1200, 1000, and 800
cGy of TBI were 5, 9, and 26, respectively. The corresponding probabilities of overall survival (OS) at 3 years
were 40%, 44%, and 92%, respectively. The incidence of regimen-related toxicity with grade III-IV and graft
rejection in the patients who received a dose of 800 cGy of TBI were 0 of 26 patients. The significant factors
associated with OS were the TBI dose (800 cGy vs. >1000 cGy; P  .001), chronic graft-versus-host disease
(less than or equal to limited vs. extensive; P  .013), the method of HLA typing for the donor-recipient
matching (serologic typing vs. DNA-based typing; P  .006), and the transfusion amount before transplanta-
tion (<90 vs. >90 units; P  .020).
© 2007 American Society for Blood and Marrow Transplantation
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bNTRODUCTION
Allogeneic bone marrow transplantation from an
nrelated donor (u-BMT) is an alternative therapy for
patient with severe aplastic anemia who cannot ac-
uire an adequate response to immunosuppressive
herapy (IST) and does not have an HLA-identical
ibling donor. Additionally, u-BMT can be a front-
ine therapy for very severe aplastic anemia when the
atient can receive emergent u-BMT without IST.
owever, the success of this approach is limited by a
igher incidence of transplant-related complications
TRC), such as graft rejection, graft-versus-host dis-
ase (GVHD), and various organ toxicities than is
een for bone marrow transplants from an HLA-iden-
ical sibling donor (s-BMT) [1-4]. u-BMT recipients rith aplastic anemia usually have the following unfa-
orable characteristics: a longer duration of disease, a
igher iron deposit in tissues, and a higher chance to
ave a preformed alloimmunity because of multiple
ransfusions required before transplant, and a higher
ntensity of pretransplant conditioning required to
vercome graft rejection [3-7]. As TRC are deeply
nﬂuenced by the intensity of the conditioning regi-
ens, it is necessary to determine the optimal inten-
ity of conditioning regimens that can both overcome
he risk of graft rejection and minimize regimen-
elated toxicities (RRT). The optimal type and opti-
al intensity of conditioning are difﬁcult to determine
ecause of a lack of prospective trials using uniﬁed
egimens. Recently, a prospective trial of Deeg and
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S.-Y. Kim et al.864olleagues [8] suggested that the combination of a low
ose of total body irradiation (TBI) plus administra-
ion of 200 mg/kg of cyclophosphamide (CY) and 90
g/kg of antithymocyte globulin (ATG) could be an
ptimal conditioning regimen for u-BMT in severe
plastic anemia. These investigators added low-dose
BI to the same conditioning regimens as those used
or HLA-matched sibling donor transplantation; CY
200 mg/kg) plus ATG. From the beginning of 1998,
e have been conducting a similar prospective trial to
etermine a safe and sufﬁcient dose of TBI to use in
ombination with 120 mg/kg of CY as a conditioning
egimen for u-BMT for aplastic anemia. In this trial,
e have employed a high dose of TBI (from a dose of
200 cGy to 800 cGy, stepwisely) and a lower dose of
Y (120 mg/kg). ATG was not incorporated in this
rotocol.
ATIENTS AND METHODS
atients
The patients enrolled in the study were either
hose with severe aplastic anemia who could receive
mergent transplants without preceding IST because
he coordination period for u-BMT was short or those
ho had not responded to IST or had responded only
ransiently. Forty patients received u-BMT using TBI
nd CY from May 1998 to February 2006 at our
nstitution. Informed consent was obtained from all
atients. As of October 2006, the median follow-up
uration period after transplant was 27 months (range:
-100 months). Patients and transplant characteristics
re summarized in Table 1. The median age of the
atients was 27 years (range: 16-50 years). The me-
ian disease duration before transplant was 39 months
range: 2-192 months). Most patients were heavily
ransfused before transplant. The median amount of
lood transfused was 81 units (range: 8-500 units).
ight patients with very severe aplastic anemia under-
ent u-BMT without preceding IST. Nineteen pa-
ients had received 1 course of conventional IST and
3 patients received more than 1 course of IST before
ransplant.
LA Typing Method for Donor-Recipient
atching
The method of HLA typing for donor-recipient
atching was determined by its availability at the time
f enrollment into the study. For the ﬁrst consecutive
6 patients, the donor-recipient was matched by se-
ologic typing for HLA-A, -B, (-C), and -DR. For the
emaining 24 patients, the donor-recipient were
atched with DNA-based typing for HLA-A, -B,
-C), and -DRB1. During the use of serologic typing,
LA-nonidentical transplants were not performed,
ut there were 4 HLA-nonidentical (antigen level in 1 end allele level in 3) transplants during the use of
NA-based typing in this trial.
retransplant Conditioning and GVHD
rophylaxis
Administration of CY at a dose of 60 mg/kg/day
or 2 days (120 mg/kg in total) was followed by TBI at
starting dose of 2  200 cGy fractions per day for 3
ays (1200 cGy in total). The TBI dose was to be
owered by 200 cGy stepwisely according to the pres-
nce of graft rejection and other TRC after transplant.
atients were treated in groups of 5, with the ﬁrst
roup receiving a dose of 1200 cGy of TBI (TBI 1200)
nd 120 mg/kg of CY (CY 120). If more than 1 patient
f the group died of TRC other than graft rejection,
he next cohort were to receive a reduced dose of TBI
y 200 cGy, stepwise. If only 1 or none of the patients
f the group died of TRCs other than graft rejection,
he patients of the next group were to receive the same
ose of TBI as the previous group. We de-escalated
he TBI dose according to the presence of life-threat-
able 1. Characteristics of 40 Patients with Aplastic Anemia Who
nderwent Unrelated Donor Bone Marrow Transplantation with a
onditioning Regimen Composed of 800-1200 cGy of Total Body
rradiation Plus 120 mg/kg of Cyclophosphamide
Characteristic
Median (Range) or
No. of Patients
(%)
ge, year 27 years (16-50)
ex (male:female) 24 (60%):16 (40%)
isease duration, month 39 months (2-192)
mount of blood transfused, units 81 units (8-500)
umber of courses of immunosuppressive
therapy
0 8 (20%)
1 19 (48%)
>1 13 (32%)
LA typing method and HLA mismatch
serological typing 16 (40%)
HLA-identical 16
HLA-nonidentical 0
DNA-based typing 24 (60%)
HLA-identical 20
HLA-nonidentical 4*
BI dose
1200 cGy 5 (12%)
1000 cGy 9 (23%)
800 cGy 26 (65%)
VHD prophylaxis
CsA  MTX 3 (8%)
FK506  MTX 37 (92%)
ell dose infused
MNC (108/kg) 1.0 (0.3-5.4)
CD34 (106/kg) 4.3 (0.8-14.4)
CD3 (107/kg) 5.0 (1.2-21.8)
VHD indicates graft-versus-host disease; TBI, total body
irradiation.
There were 4 HLA-nonidentical (antigen level in 1 and allele level
in 3) transplants according to DNA-based typing.ning TRC rather than RRT because infection and
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Intermediate TBI Dose for u-BMT for Aplastic Anemia 865VHD are the important TRC that are closely asso-
iated with conditioning intensity but are not included
n the category of RRT [9]. For GVHD prophylaxis,
he ﬁrst 3 patients received cyclosporine and short
ourse methotrexate [10]. The remaining 37 patients
eceived tacrolimus and short-course methotrexate
11]. Cyclosporine (CSa) and tacrolimus were admin-
stered to patients until day 180, or more according, to
he presence of GVHD.
ngraftment and TRC
Engraftment was deﬁned as the ﬁrst of 3 consec-
tive days with a neutrophil count that exceeded 0.5
09/L. Primary graft failure was deﬁned as failure to
chieve a neutrophil count of 0.5  109/L for 3
onsecutive days at any time posttransplantation. Sec-
ndary graft failure was deﬁned as the development of
n absolute neutrophil count of 0.5  109/L after
nitial engraftment had been already achieved. RRT
as graded by use of the Bearman score [9]. Acute
VHD (aGVHD) was graded as recommended by
he aGVHD grading consensus conference [12].
hronic GVHD (cGVHD) was assessed as none, lim-
ted, or extensive [13].
tatistical Method
The differences of the categoric variables between
he study groups were analyzed with the Pearson chi-
quare and Fisher’s exact tests. Survival curves were
lotted using the Kaplan-Meier method. The differ-
able 2. Outcomes of 40 Patients with Aplastic Anemia Who Underwe
onditioning with Total Body Irradiation Plus Cyclophosphamide
No. of Affect
Variable TBI 1200 Group TBI 1000 Gr
umber 5 (12.5) 9 (22.5)
raft failure
None 5 (100) 8 (89)
Primary 0 1* (11)
Secondary 0 0
egimen-related toxicity
Maximal grade, 0-1 1 (20) 3 (33)
Maximal grade, 2 4 (80) 6 (67)
Maximal grade, 3-4 0 0
cute GVHD
Grade 0-1 2 (40) 8 (89)
Grade 2 3 (60) 1 (11)
Grade 3-4 0 0
hronic GVHD‡
None 2 (40) 4 (80)
Limited 0 0
Extensive 3 (60) 1 (20)
urvival 2 (40) 4 (44)
VHD indicates graft-versus-host disease; TBI, total body irradiat
The cause of primary graft failure was graft rejection.
The cause of secondary graft failure was CMV infection and ganc
The numbers of evaluated patients for chronic GVHD were 5, 5,nces of overall survival (OS) between the groups with tespect to variables were analyzed with the log-rank
est. The P-values reported were 2-sided and P  .05
as considered signiﬁcant. All analyses were per-
ormed using the Statistical Package for the Social
ciences (SPSS) software, version 12.0 (SPSS 12.0
nc., Chicago, IL).
ESULTS
The transplantation outcomes are summarized in
able 2. Patients were followed for a median of 27
onths (range: 1-100 months). The median follow-up
eriod for surviving patients was 37 months (range:
-100 months). Among the ﬁrst 5 patients who re-
eived a dose of 1200 cGy of TBI (TBI 1200 group),
patients (60%) died of TRC, and therefore, the
atients in the next group received a decreased dose of
BI of 1000 cGy (TBI 1000 group). Because the
econd group seemed to have an initially good out-
ome, we planned to give another 5 patients a dose of
000 cGy of TBI. However, because 2 patients of the
econd group died of TRC during the third group
rial, we de-escalated the TBI dose to 800 cGy begin-
ing from the 15th patient on (TBI 800 group). The
utcome of u-BMT using a dose of 800 cGy of TBI
as been continuously satisfactory, and all remaining
atients have received this dose.
ngraftment
Thirty-eight (95%) out of 40 patients had sus-
Marrow Transplants from an Unrelated Donor Who Received
ients (%) P-Value
TBI 800 Group Overall (TBI 1000-1200 vs. TBI 800)
26 (65) 40 (100)
.368
25 (96) 38 (95)
0 1 (2.5)
1† (4) 1 (2.5)
.026
17 (65) 21 (53)
9 (35) 19 (47)
0 0
.198
18 (69) 28 (70)
8 (31) 12 (30)
0 0
.155
15 (69) 21 (62)
5 (23) 5 (15)
4 (8) 8 (23)
24 (92) 30 (75) .001
treatment.
in the TBI 1200, TBI 1000, and TBI 800 groups, respectively.nt Bone
ed Pat
oup
ion.
iclovirained engraftment until the last follow-up. The me-
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S.-Y. Kim et al.866ian time to engraftment was 14 days (range: 9-24
ays) and the median time to platelet recovery, de-
ned as a platelet count 20  109/L without trans-
usional support, was 29 days (range: 10-200 days).
ne patient showed a delayed platelet recovery until
00 days posttransplant, but his platelet count rose
lowly to the normal level thereafter. Two (5%) of 40
atients experienced graft failure. One patient who
eceived a dose of 1000 cGy of TBI had primary graft
ailure because of graft rejection. The patient received
peripheral blood stem cell transplant from the same
onor as a rescue, but died of infection without he-
atologic recovery. The other patient, who received a
ose of 800 cGy of TBI, showed secondary graft
ailure at the 6th month after transplant. The cause of
econdary graft failure may have resulted from cyto-
egalovirus (CMV) infection and ganciclovir treat-
ent, rather than from graft rejection. The patient
uffered from CMV antigenemia and received ganci-
lovir before the secondary graft failure occurred. The
one marrow chimerism of the patient was revealed as
he donor type of 100% at the time of graft failure by
olymerase chain reaction analysis of short tandem
epeat sequences. The patient received a booster of
one marrow stem cells from the same donor on the
4th month after transplant and he recovered from
ytopenia and is still alive with normal blood counts.
he overall rate of graft rejection was 1 of 40 (2.5%).
egimen-Related Toxicity
The incidence of a maximal RRT grade II was
igniﬁcantly higher in the TBI 1000-1200 groups (10/
4, 71%) than in the TBI 800 group (9/26, 35%) (P
046). The most frequent RRT grade II is stomatitis
n  14) followed by gastrointestinal toxicity (n  1),
ladder toxicity (n  1), renal toxicity (n  1), hepatic
oxicity (n  1), and CNS toxicity (n  1). There was
o cardiac and pulmonary toxicity grade II. How-
ver, none of the 40 patients experienced grade III or
V RRT, which suggested that the combination of a
ose of 1200 cGy or less of TBI plus CY 120 was a
enerally tolerable regimen for u-BMT for aplastic
nemia in terms of RRT.
GVHD and cGVHD
The overall incidence of aGVHD was 18 of 40
45%) but no patient had an aGVHD grade III-IV,
hich shows that the clinical manifestations of
GVHD in a u-BMT setting with these conditioning
egimens for aplastic anemia were mild to moderate.
here was a trend toward an increased incidence of
GVHD in the TBI 1200-1000 groups (57%) com-
ared with the TBI 800 group (38%), but this trend
as not statistically signiﬁcant (P  .327). The inci-
ence of cGVHD was 13 (38%) of 34 evaluated pa-
ients, and 8 (23%) patients had extensive cGVHD. ahe incidence of extensive cGVHD was higher in the
BI 1200-1000 groups (4 of 10; 40%) than in the TBI
00 group (4 of 20; 20%), but this was also not sta-
istically signiﬁcant (P  .195).
ause of Death
The number of deaths was 10 (25%) of 40 pa-
ients. The causes of death are listed in Table 3. The
auses of death of the patients who died before day
00 posttransplant were infection (n  4), graft rejec-
ion (n  1), and posttransplant thrombotic microan-
iopathy (n  1). The causes of death of the patients
ho died after day 100 posttransplant were extensive
GVHD (n  3) and hepatitis B (n  1). Five of 6
atients who died in the early posttransplant period
id not have aGVHD, and the remaining 1 patient
ad aGVHD grade I, which indicated that aGVHD
as not an important cause of death in this study
roup. Meanwhile, extensive cGVHD was the main
ause of death after 100 days posttransplant. There
as been no posttransplant malignancies until the last
ollow-up, such as posttransplant lymphoproliferative
isorder and solid tumors, which were reported in
arlier reports [14,15].
urvival
As of October 2006, 30 (75%) of 40 patients are
urviving with normal blood counts. The probabilities
f OS at 3 years were 40%, 44%, and 92% in the TBI
200, 1000, and 800 cGy groups, respectively. The
atient who experienced secondary graft failure has
lso been showing normal blood counts after a booster
ith bone marrow stem cells from the same donor.
he TBI dose (800 cGy vs. 1000 cGy), cGVHD
less than or equal to limited vs. extensive), the
ethod of HLA typing (DNA-based vs. serologic),
able 3. Causes of Death in Unrelated Donor Bone Marrow
ransplantation for Aplastic Anemia with a Conditioning Regimen of
00-1200 cGy of Total Body Irradiation Plus 120 mg/kg of
yclophosphamide
No. of Patients
Cause of Death TBI  800 cGy TBI > 1000 cGy
hronic extensive GVHD 0 3 (6,12,14)*
MV pneumonia 0 1 (2)
ungal pneumonia 0 1 (2)
ucormycosis 0 1 (3)
raft rejection 0 1 (2)
epatitis B 0 1 (7)
epsis 1 (1) 0
osttransplant thrombotic
microangiopathy 1 (1) 0
MV indicates cytomegalovirus; TBI, total body irradiation;
GVHD, graft-versus-host disease.
The numbers in the parentheses indicate time (months) to death
after transplant.nd the amount of blood transfusion before transplant
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Intermediate TBI Dose for u-BMT for Aplastic Anemia 86790 vs. 90 units) were the statistically signiﬁcant
actors inﬂuencing survival (P  .001, .013, .006, and
020, respectively; Figure 1). Age, the presence of an
LA mismatch, and the interval time from diagnosis
o transplant were not signiﬁcant factors based on
tatistical analysis.
ISCUSSION
Until now, only a few prospective trials had been
onducted to ﬁnd the optimal intensity and optimal
ype of conditioning regimens for bone marrow trans-
lantation from an u-BMT for aplastic anemia
8,16,17]. Recently, the prospective trial of Deeg and
olleagues [8] has suggested that the combination of
ow-dose TBI (200 cGy) and CY (200 mg/kg) and
TG (90 mg/kg) is an optimal regimen. These inves-
igators added low-dose TBI to the same conditioning
egimens as those used for S-BMT. The OS of the
atients who received TBI 200 plus CY 200 plus ATG
igure 1. A, OS of unrelated bone marrow transplantation in sever
, transfusion amount before transplant. P-values were determinedor conditioning were 23 of 35 (66%) for the HLA satched u-BMT and 5 of 11 (45%) for the HLA-
ismatched u-BMT.
In 1998, we planned a prospective trial to determine
n optimal conditioning regimen using TBI and CY. In
previous pilot study of 5 patients who received u-BMT
ollowing CY/ATG conditioning when used for recipi-
nts of HLA-identical unrelated donor marrow, 3 pa-
ients experienced graft failure and only 1 patient sur-
ived long term [17]. Therefore, we thought that, to
vercome the graft failure, the use of a more intensive
onditioning regimen could eradicate both the abnormal
ematopoietic stem cells and abnormal immune cells of
he recipient that are suggested to be the causes of the
evelopment of aplastic anemia and the use of TBI and
Y, so-called traditional standard conditioning regimens
hat had been themost widely used in the transplantation
eld, were chosen for this trial.
Our results show that the combination of TBI 800
lus CY 120 was sufﬁcient and safe for conditioning of
-BMT for aplastic anemia. No graft rejection was
tic anemia by TBI dose; B, HLA typing method; C, cGVHD; and
log-rank test.e aplaseen for patients in the TBI 800 group. Although 1
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S.-Y. Kim et al.868atient who received a dose of 800 cGy of TBI had
econdary graft failure, it was not from the graft re-
ection, and he continues to survive with a normal
lood count after a booster with bone marrow stem
ells from the same donor. The OS was 24 of 26
92%) in this group, which is comparable to a previ-
usly reported outcome of sibling donor transplant for
plastic anemia [18-20]. In addition, no grade III-IV
RT was seen in the TBI 800 group in contrast to
arlier trials where the incidence of life-threatening
RT in the high dose TBI (1200 cGy or more) group
as high [8,21]. The incidence of RRT grade III for
ow-dose TBI plus CY 200 plus ATG in the trial of
eeg and colleagues [8] was 21%, which seems to be
igher than that of our study group (0%) despite the
ower dose of TBI employed than in the present trial,
hich suggests the higher dose of the chemotherapy
CY 200 mg/kg) might affect RRT, rather than the
dditional radiation. The low incidence of aGVHD
lso might reduce the risk of severe RRT in our group
f patients because aGVHD is a systemic alloimmune
isease that is mediated by multiple complex cytokines
nd can inﬂuence RRT, including lung toxicity and
osttransplant thrombotic microangiopathy [22-24],
ven though its grade is determined only using the
kin, liver, and gut.
The overall incidences of grade II-IV aGVHD
nd cGVHD in this trial were 30% and 38%, respec-
ively, which are similar to those seen in an earlier
arge study from Japan where 29% of patients experi-
nced grade II-IV aGVHD and 30% of the patients
ad cGVHD [5]. However, these values are smaller
han those reported earlier by Deeg and colleagues
8], where the incidences of grade II-IV aGVHD and
GVHD were 69%-77% and 52%-57%. The low
ncidence of GVHD, particularly of severe aGVHD,
ight in part be related to a more limited gene pool in
he Korean population than exists in European and
orth American populations. According to recently
nalyzed data in our institution, the incidence of
GVHD in acute myelogenous leukemia (AML) pa-
ients who underwent an unrelated donor transplant
sing TBI and CY was also low (36%, unpublished
ata). The differences in the incidence of GVHD also
ake it difﬁcult to compare the outcome of this trial
ith those of the other earlier trials using a different
onditioning regimen because GVHD can affect the
utcome of transplantation. This trial found no sta-
istically signiﬁcant difference in the incidence of
GVHD and extensive cGVHD between the TBI
200-1000 groups and the TBI 800 group, but showed
trend toward an increased incidence of GVHD in
he higher TBI group (P  .198 and .195, respec-
ively). Life-threatening infection and GVHD, main
auses of death in our study subjects, are not deﬁned as
RT but are known to be related with the intensity of
onditioning [25,26]. This may be why patients in the iBI 1200-1000 groups did not show a good outcome
ike those in the TBI 800 group despite a low inci-
ence of life-threatening RRT.
We matched donor and recipient with either se-
ologic or DNA-based HLA typing according to the
vailability of the HLA typing method at the time of
ransplant. Therefore, the early-trial groups (TBI
000-1200 groups) used serologic HLA typing and
he late-trial group (TBI 800 group) used mainly
NA-based HLA typing for the matching program.
ll patients who received TBI 1000-1200 (n  14)
ere matched with serologic typing. Only 2 patients
14%) of the TBI 800 group were matched with the
erologic method, and 24 patients (86%) of the TBI
00 group were matched with donors by DNA-based
yping. DNA-based HLA typing is now widely used in
he stem cell transplantation ﬁeld because many clin-
cal studies have conﬁrmed a better outcome in trans-
lantation with the high-resolution HLA typing not
nly for aplastic anemia but also for other hematologic
alignant diseases [5,27-30]. Kojima and colleagues
5] have examined the HLA of serologically identical
nrelated donor transplantation with the DNA-based
yping method retrospectively, and found that even
or a serologically identical donor, HLA-identical
ransplantation by DNA-based typing showed a more
avorable outcome than HLA-nonidentical transplan-
ation by DNA-based typing for aplastic anemia. The
LA typing method is a confounding factor that
ade it difﬁcult to interpret the independent effect of
he TBI dose for our results. Because the method of
LA typing is also a signiﬁcant factor for outcome
P  .031) in this trial as determined by univariate
nalysis, the improved outcome of the TBI 800 group
P  .008) cannot be explained by the TBI dose
ndependently from the HLA typing method, statisti-
ally. Because of this confounding factor and the small
umber of subjects in this trial, multivariate analysis
id not indicate any signiﬁcant independent prognos-
ic factors. However, all patients who underwent u-
MT with an HLA-matched donor determined by
erologic typing (n  2) and with an HLA-mis-
atched donor determined by DNA-based typing
n  4) in the TBI 800 group are surviving long term,
nd none of them had RRT grade III-IV. This sug-
ests the combination of TBI 800 and CY 120 can be
n acceptable conditioning regimen even in a trans-
lant from an HLA-mismatched unrelated donor
ased on DNA-based typing if the degree of mismatch
s low.
This trial indicates a large amount of transfused
lood before transplant is an unfavorable prognostic
actor but the time interval from diagnosis to trans-
lant is not a signiﬁcant prognostic factor, which
ight suggest that the degree of exposure to alloan-
igen and the amount of transfused blood are more
mportant than the disease duration. This may be
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Intermediate TBI Dose for u-BMT for Aplastic Anemia 869ecause the preformed alloimmunity from the previ-
us transfusion can affect graft rejection and the
igher iron overload can affect the incidence of RRT
nd infection [6,7,31-33]. The age of the patient at
ransplant is also known to be an important factor for
he outcome of transplant for aplastic anemia [5,8,34].
owever, the analysis of this trial was not consistent
ith previous ﬁndings, possibly because this study
opulation conﬁned the adult and range of the age of
he patients (from 16-50 years; median: 27 years) was
arrower compared to earlier reports, and the study
opulation was too small to determine the inﬂuence of
hese factors.
A comparison between the use of TBI 800/CY 120
nd other conditioning regimens used in the other
tudy groups is difﬁcult to make because of the small
umber of subjects in this trial and different charac-
eristics of the patients from other prior trials. How-
ver, the present results indicate that an intermediate
ose of TBI (800 cGy) used in combination with CY
20 can also be a considerable conditioning regimen
or unrelated donor transplant for aplastic anemia,
specially in conjunction with the use of high-resolu-
ion HLA typing, which is not only sufﬁcient to over-
ome graft rejection and sustain engraftment, but is
lso safe in terms of other TRC.
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